FDA Acting Commissioner Crawford Touts Benefits Of DTC Advertising
This article was originally published in The Pink Sheet Daily
Executive Summary
Crawford emphasizes the need for industry self-regulation of direct-to-consumer promotion at Biotechnology Industry Organization/Windhover conference. The acting commissioner's remarks are softer than his recent calls for FDA enforcement action against "out of hand" DTC ads.
You may also be interested in...
DTC Advertising "Tone-Down" Could Address FDA Concerns, Schering Says
Marketers will begin airing more balanced DTC ads as a result of increased scrutiny from FDA about the quality of some ads, Schering CFO Bertolini says. With Levitra, Schering now participates in what may be a high-risk market for DTC ads: erectile dysfunction disorder.
DTC Advertising "Tone-Down" Could Address FDA Concerns, Schering Says
Marketers will begin airing more balanced DTC ads as a result of increased scrutiny from FDA about the quality of some ads, Schering CFO Bertolini says. With Levitra, Schering now participates in what may be a high-risk market for DTC ads: erectile dysfunction disorder.
Nexium Branded Campaign Will Highlight Use With NSAIDs
AstraZeneca says the ads will debut "within the coming weeks." The spots will conform to the company's new principles that highlight "direct" presentation of risk/benefit information and the benefits of early detection.